OR WAIT null SECS
© 2023 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
Applied Clinical Trials
Commissioned by Roche Germany, IDDI has found data that suggests that it is appropriate to use disease-free survival as a surrogate for overall survival in trials in HER-2-positive breast cancer.
To learn more about their findings, click here.